Similar companies
Income Statement (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Revenue | 750,000 | 4.2% |
| Gross Profit | 750,000 | 4.2% |
| Operating expense | 29M | 12.3% |
| Net Income | -61M | 120.3% |
| EBITDA | -61M | 123.6% |
Balance Sheet (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Total Assets | 240M | 26.8% |
| Total Liabilities | 80M | 76.5% |
| Total Equity | 160M | 11.1% |
| Shares Outstanding | 218M | 10.7% |
Cash Flow (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Cash from operations | -23M | 65% |
| Cash from investing | -68M | 790.4% |
| Cash from financing | 60M | 670.2% |
EPS
Financial Highlights for ATAI Life Sciences in Q3 '25
ATAI Life Sciences reported a revenue of 750,000, which is a 4.2% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 750,000, marking a 4.2% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Operating Expenses for this period were 29M, showing a 12.3% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -61M, showing a -120.3% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -61M, showing a -123.6% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
ATAI Life Sciences faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies. A decline in EBITDA signals potential operational challenges or increased costs.
